Actavis’ Brent Saunders And Paul Bisaro Talk Innovation Vs. Discovery
This article was originally published in The Pink Sheet Daily
Executive Summary
Incoming CEO and executive chairman of the Actavis/Forest colossus discuss the end of “me-too” drugs and the future of R&D in an interview with “The Pink Sheet” DAILY.
You may also be interested in...
Levin Calls Takeda/Shire Merger ‘Inspired,’ Says Entire Value Chain Must Address Pricing Issue
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Valeant Sheds Staff, Creates Executive Panel After Bausch & Lomb Deal
The fast-growing, Canadian specialty pharma will shed more than 2,700 jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.